Difference between revisions of "Part:BBa K5302002:Experience"
(→Applications of BBa_K5302002) |
(→Applications of BBa_K5302002) |
||
| Line 7: | Line 7: | ||
This year, the USTC iGEM team has utilized the competitive binding of vascular endothelial growth factor (VEGF) to develop a targeted bacterial therapy for solid tumors. Our quest for the optimal VEGF-binding protein(or peptide) led us to an in-depth exploration of proteins structurally akin to the vascular endothelial growth factor receptor (VEGFR), which we have named VEGFR-like. | This year, the USTC iGEM team has utilized the competitive binding of vascular endothelial growth factor (VEGF) to develop a targeted bacterial therapy for solid tumors. Our quest for the optimal VEGF-binding protein(or peptide) led us to an in-depth exploration of proteins structurally akin to the vascular endothelial growth factor receptor (VEGFR), which we have named VEGFR-like. | ||
8IIU is an anti-VEGF nanobody, and it has 2 chains.These two chains all show great affinity with VEGF, we used pBBR1MCS-2 plasmid as a backbone and transfered 8IJZ into Escherichia coli Nissle 1917,and finally succeeded in expressing 8IJZ. | 8IIU is an anti-VEGF nanobody, and it has 2 chains.These two chains all show great affinity with VEGF, we used pBBR1MCS-2 plasmid as a backbone and transfered 8IJZ into Escherichia coli Nissle 1917,and finally succeeded in expressing 8IJZ. | ||
| + | |||
| + | [1]Zhu S, Fan S, Tang T, Huang J, Zhou H, Huang C, Chen Y, Qian F. Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration. Bioeng Transl Med. 2023 May 4;8(6):e10523. doi: 10.1002/btm2.10523. PMID: 38023710; PMCID: PMC10658565. | ||
===User Reviews=== | ===User Reviews=== | ||
Latest revision as of 04:26, 1 October 2024
This experience page is provided so that any user may enter their experience using this part.
Please enter
how you used this part and how it worked out.
Applications of BBa_K5302002
This year, the USTC iGEM team has utilized the competitive binding of vascular endothelial growth factor (VEGF) to develop a targeted bacterial therapy for solid tumors. Our quest for the optimal VEGF-binding protein(or peptide) led us to an in-depth exploration of proteins structurally akin to the vascular endothelial growth factor receptor (VEGFR), which we have named VEGFR-like. 8IIU is an anti-VEGF nanobody, and it has 2 chains.These two chains all show great affinity with VEGF, we used pBBR1MCS-2 plasmid as a backbone and transfered 8IJZ into Escherichia coli Nissle 1917,and finally succeeded in expressing 8IJZ.
[1]Zhu S, Fan S, Tang T, Huang J, Zhou H, Huang C, Chen Y, Qian F. Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration. Bioeng Transl Med. 2023 May 4;8(6):e10523. doi: 10.1002/btm2.10523. PMID: 38023710; PMCID: PMC10658565.
User Reviews
UNIQ8346752124e6bece-partinfo-00000000-QINU UNIQ8346752124e6bece-partinfo-00000001-QINU